This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Chronic obstructive pulmonary disease (COPD) and b...
  • /
  • New developments in optimizing bronchodilator trea...
Journal

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology.

Read time: 1 mins
Published:7th Sep 2018
Author: D'Urzo AD, Cazzola M, Hanania NA, Buhl R, Maleki-Yazdi MR.
Availability: Free full text
Ref.:Int J Chron Obstruct Pulmon Dis. 2018;13:2805-2819.
DOI:10.2147/COPD.S113306

COPD causes considerable health and economic burden worldwide, with incidence of the disease expected to continue to rise. Inhaled bronchodilators, such as long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs), are central to the maintenance treatment of patients with COPD. Clinical studies have demonstrated that combined LAMA + LABA therapies improve efficacy while retaining a safety profile similar to LAMA or LABA alone.

This has led to the development of several LAMA/LABA fixed-dose combination (FDC) therapies, which provide patients with the convenience of two active compounds in a single inhaler. GFF MDI (Bevespi Aerosphere®) is an FDC of glycopyrrolate/formoterol fumarate 18/9.6 µg formulated using innovative co-suspension delivery technology for administration via metered dose inhaler (MDI). GFF MDI was developed to make a treatment option available for patients who have a requirement or preference to use an MDI, rather than a dry powder or soft mist inhaler. Now that several LAMA/LABA FDCs have been approved for use in COPD, we review the impact of dual-bronchodilator treatment on COPD therapy and discuss recent clinical studies that are helping to develop a more comprehensive understanding of how LAMA/LABA FDCs can improve patient outcomes.

 

Read abstract on library site

Access full article